Literature DB >> 16754777

The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).

Nikolas von Bubnoff, Sivahari Prasad Gorantla, Silvia Thöne, Christian Peschel, Justus Duyster.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16754777     DOI： 10.1182/blood-2006-01-0285

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  11 in total

1.  Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.

Authors:  Ellen Weisberg; Hwan Geun Choi; Arghya Ray; Rosemary Barrett; Jianming Zhang; Taebo Sim; Wenjun Zhou; Markus Seeliger; Michael Cameron; Mohammed Azam; Jonathan A Fletcher; Maria Debiec-Rychter; Mark Mayeda; Daisy Moreno; Andrew L Kung; Pasi Antero Janne; Roya Khosravi-Far; Junia V Melo; Paul W Manley; Sophia Adamia; Catherine Wu; Nathanael Gray; James D Griffin
Journal:  Blood       Date:  2010-03-18       Impact factor: 22.113

2.  Overexpression of inhibitor of DNA-binding 2 attenuates pulmonary fibrosis through regulation of c-Abl and Twist.

Authors:  Jibing Yang; Miranda Velikoff; Manisha Agarwal; Supparerk Disayabutr; Paul J Wolters; Kevin K Kim
Journal:  Am J Pathol       Date:  2015-02-03       Impact factor: 4.307

Review 3.  Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.

Authors:  Peter Valent; Gerald J Gleich; Andreas Reiter; Florence Roufosse; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Karl Sotlar; Joseph H Butterfield; Sabine Cerny-Reiterer; Matthias Mayerhofer; Peter Vandenberghe; Torsten Haferlach; Bruce S Bochner; Jason Gotlib; Hans-Peter Horny; Hans-Uwe Simon; Amy D Klion
Journal:  Expert Rev Hematol       Date:  2012-04       Impact factor: 2.929

4.  Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib.

Authors:  Massimo Breccia; Giuliana Alimena
Journal:  Onco Targets Ther       Date:  2008-10-01       Impact factor: 4.147

5.  Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.

Authors:  Krisna C Duong-Ly; Karthik Devarajan; Shuguang Liang; Kurumi Y Horiuchi; Yuren Wang; Haiching Ma; Jeffrey R Peterson
Journal:  Cell Rep       Date:  2016-01-14       Impact factor: 9.423

Review 6.  Nilotinib: a novel, selective tyrosine kinase inhibitor.

Authors:  Jean-Yves Blay; Margaret von Mehren
Journal:  Semin Oncol       Date:  2011-04       Impact factor: 4.929

7.  Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.

Authors:  Irina Sadovnik; Els Lierman; Barbara Peter; Harald Herrmann; Verena Suppan; Gabriele Stefanzl; Oskar Haas; Thomas Lion; Winfried Pickl; Jan Cools; Peter Vandenberghe; Peter Valent
Journal:  Exp Hematol       Date:  2014-01-06       Impact factor: 3.084

8.  Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia.

Authors:  Yoshiyuki Yamada; Marc E Rothenberg; Jose A Cancelas
Journal:  Transl Oncogenomics       Date:  2006-12-05

9.  Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.

Authors:  Violaine Havelange; Jean-Baptiste Demoulin
Journal:  J Blood Med       Date:  2013-08-09

Review 10.  Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Authors:  Ayalew Tefferi
Journal:  J Cell Mol Med       Date:  2008-10-23       Impact factor: 5.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.